Details for Patent: 7,005,122
✉ Email this page to a colleague
Title: | Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
Abstract: | The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing sumatriptan, frovatriptan, or naratriptan that are used in inhalation therapy. In a method aspect of the present invention, sumatriptan, frovatriptan, or naratriptan is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of sumatriptan, frovatriptan, or naratriptan on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering sumatriptan, frovatriptan, or naratriptan through an inhalation route is provided which comprises: a) a thin coating of a sumatriptan, frovatriptan, or naratriptan composition; and, b) a device for dispending said thin coating as a condensation aerosol. |
Inventor(s): | Hale; Ron L. (Woodside, CA), Rabinowitz; Joshua D. (Mountain View, CA), Solas; Dennis W. (San Francisco, CA), Zaffaroni; Alejandro C. (Atherton, CA) |
Assignee: | Alexza Pharmaceutical, Inc. (Palo Alto, CA) |
Filing Date: | Mar 03, 2004 |
Application Number: | 10/791,915 |
Claims: | 1. A dose form of sumatriptan comprising a condensation aerosol formed by heating a thin layer containing sumatriptan, on a solid support, to produce a vapor of sumatriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% sumatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 20 mg of sumatriptan. 2. A dose form of frovatriptan comprising a condensation aerosol formed by heating a thin layer containing frovatriptan, on a solid support, to produce a vapor of frovatriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% frovatriptan degradation products by weight, and MMAD of less than 5 microns, wherein the dose form comprises less than 2 mg of frovatriptan. 3. A dose form of naratriptan comprising of a condensation aerosol formed heating a thin layer containing naratriptan, on a solid support, to produce a vapor of naratriptan and condensing the vapor to form a condensation aerosol characterized by less than 10% naratriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 0.8 mg of naratriptan. 4. A method of producing a dose form of sumatriptan comprising a condensation aerosol, the method comprising: a. heating a thin layer containing sumatriptan, on a solid support, to produce a vapor of sumatriptan, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% sumatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 20 mg of sumatriptan. 5. A method of producing a dose form of frovatriptan comprising a condensation aerosol, the method comprising: a. heating a thin layer containing frovatriptan, on a solid support, to produce a vapor of frovatriptan, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% frovatriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 2 mg of frovatriptan. 6. A method of producing a dose form of naratriptan comprising a condensation aerosol, the method form comprising: a. heating a thin layer containing naratriptan on a solid support, to produce a vapor of naratriptan, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% naratriptan degradation products by weight, and an MMAD of less than 5 microns, wherein the dose form comprises less than 0.8 mg of naratriptan. |